Computational Insight into Protein Tyrosine Phosphatase 1B Inhibition: A Case Study of the Combined Ligand- and Structure-Based Approach

Protein tyrosine phosphatase 1B (PTP1B) is an attractive target for treating cancer, obesity, and type 2 diabetes. In our work, the way of combined ligand- and structure-based approach was applied to analyze the characteristics of PTP1B enzyme and its interaction with competitive inhibitors. Firstly, the pharmacophore model of PTP1B inhibitors was built based on the common feature of sixteen compounds. It was found that the pharmacophore model consisted of five chemical features: one aromatic ring (R) region, two hydrophobic (H) groups, and two hydrogen bond acceptors (A). To further elucidate the binding modes of these inhibitors with PTP1B active sites, four docking programs (AutoDock 4.0, AutoDock Vina 1.0, standard precision (SP) Glide 9.7, and extra precision (XP) Glide 9.7) were used. The characteristics of the active sites were then described by the conformations of the docking results. In conclusion, a combination of various pharmacophore features and the integration information of structure activity relationship (SAR) can be used to design novel potent PTP1B inhibitors.

[1]  Wei Li,et al.  Structure‐Based Optimization of Protein Tyrosine Phosphatase‐1 B Inhibitors: Capturing Interactions with Arginine 24 , 2008, ChemMedChem.

[2]  Soroush Sardari,et al.  Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents , 2017, J. Chem. Inf. Model..

[3]  D. Barford,et al.  Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. , 1995, Science.

[4]  Birger Lindberg Møller,et al.  High-resolution PTP1B inhibition profiling combined with high-performance liquid chromatography-high-resolution mass spectrometry-solid-phase extraction-nuclear magnetic resonance spectroscopy: Proof-of-concept and antidiabetic constituents in crude extract of Eremophila lucida. , 2016, Fitoterapia.

[5]  T. Burke,et al.  Phosphotyrosyl mimetics in the development of signal transduction inhibitors. , 2003, Accounts of chemical research.

[6]  Wei Li,et al.  Evaluation of 147 Kampo prescriptions as novel protein tyrosine phosphatase 1B (PTP1B) inhibitory agents , 2014, BMC Complementary and Alternative Medicine.

[7]  Sarath Kumar Baskaran,et al.  Molecular Dynamics Approach to Probe the Allosteric Inhibition of PTP1B by Chlorogenic and Cichoric Acid , 2012, J. Chem. Inf. Model..

[8]  Mao-Sheng Cheng,et al.  In Silico Design of Human IMPDH Inhibitors Using Pharmacophore Mapping and Molecular Docking Approaches , 2015, Comput. Math. Methods Medicine.

[9]  Michael Bower,et al.  Structural Basis for Inhibition of Protein-tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics* , 2006, Journal of Biological Chemistry.

[10]  Qian Zhang,et al.  Modeling Compound-Target Interaction Network of Traditional Chinese Medicines for Type II Diabetes Mellitus: Insight for Polypharmacology and Drug Design , 2013, J. Chem. Inf. Model..

[11]  Lydia Tabernero,et al.  Protein tyrosine phosphatase structure–function relationships in regulation and pathogenesis , 2013, The FEBS journal.

[12]  Wang Shen,et al.  Allosteric inhibition of protein tyrosine phosphatase 1B , 2004, Nature Structural &Molecular Biology.

[13]  Michael P. Myers,et al.  Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate , 2003, Nature.

[14]  P G Drake,et al.  Structural and Evolutionary Relationships among Protein Tyrosine Phosphatase Domains , 2001, Molecular and Cellular Biology.

[15]  Tingjun Hou,et al.  Assessing an Ensemble Docking-Based Virtual Screening Strategy for Kinase Targets by Considering Protein Flexibility , 2014, J. Chem. Inf. Model..

[16]  Rebecca Page,et al.  PTP1B inhibition suggests a therapeutic strategy for Rett syndrome. , 2015, The Journal of clinical investigation.

[17]  D. Barford,et al.  Crystal structure of human protein tyrosine phosphatase 1B. , 1994, Science.

[18]  Tingjun Hou,et al.  Development and Evaluation of an Integrated Virtual Screening Strategy by Combining Molecular Docking and Pharmacophore Searching Based on Multiple Protein Structures , 2013, J. Chem. Inf. Model..

[19]  Joanna M. Sasin,et al.  Protein Tyrosine Phosphatases in the Human Genome , 2004, Cell.

[20]  A. Moretto,et al.  Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors. , 2006, Bioorganic & medicinal chemistry.

[21]  Rajendra Kumar,et al.  Probing Interaction Requirements in PTP1B Inhibitors: A Comparative Molecular Dynamics Study , 2010, J. Chem. Inf. Model..

[22]  D. Barford,et al.  The structure and mechanism of protein phosphatases: insights into catalysis and regulation. , 1998, Annual review of biophysics and biomolecular structure.

[23]  Youyong Li,et al.  Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease through Comparative Structure-Based Virtual Screening , 2017, J. Chem. Inf. Model..

[24]  Jonathan Chernoff,et al.  Regulation of the catalytic activity of PTP1B: roles for cell adhesion, tyrosine residue 66, and proline residues 309 and 310. , 2005, Experimental cell research.

[25]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[26]  Claude Dufresne,et al.  Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor. , 2008, Bioorganic & medicinal chemistry letters.

[27]  K. Lindorff-Larsen,et al.  Conformational Rigidity and Protein Dynamics at Distinct Timescales Regulate PTP1B Activity and Allostery. , 2017, Molecular cell.

[28]  Hiroyuki Yamazaki,et al.  Asperdichrome, an unusual dimer of tetrahydroxanthone through an ether bond, with protein tyrosine phosphatase 1B inhibitory activity, from the Okinawan freshwater Aspergillus sp. TPU1343 , 2016 .

[29]  A. Moretto,et al.  Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site. , 2007, Journal of medicinal chemistry.

[30]  Zhen Xu,et al.  Computational Insight into p21‐Activated Kinase 4 Inhibition: A Combined Ligand‐ and Structure‐Based Approach , 2014, ChemMedChem.

[31]  J. Dixon,et al.  Protein tyrosine phosphatases: mechanisms of catalysis and regulation. , 1998, Current opinion in chemical biology.

[32]  Richard Wynn,et al.  Structural Insights into the Design of Nonpeptidic Isothiazolidinone-containing Inhibitors of Protein-tyrosine Phosphatase 1B* , 2006, Journal of Biological Chemistry.

[33]  Young-Bum Kim,et al.  Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-Deficient Mice , 2000, Molecular and Cellular Biology.

[34]  Xiangqian Li,et al.  The design strategy of selective PTP1B inhibitors over TCPTP. , 2016, Bioorganic & medicinal chemistry.

[35]  D. Barford,et al.  Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. , 2000, Molecular cell.

[36]  Johan Wouters,et al.  Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target-based approach. , 2006, Journal of medicinal chemistry.

[37]  Zhon-Yin Zhang,et al.  Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors. , 2008, Journal of the American Chemical Society.